ReCor Medical

Courtesy of ReCor Medical

M&A status: En vogue. ReCor Medical hasn't exactly been on the tips of lips around the industry, but that's likely to change. ReCor toils in renal denervation, the hottest space in the industry, and, now that Boston Scientific ($BSX) has put down $425 million to buy Fierce 15 winner Vessix Vascular, ReCor is the last remaining private outfit with a CE-marked hypertension device. The rest of the renal denervation horde uses radiofrequency energy to ablate arterial nerves, but ReCor's device, Paradise, uses high-frequency sound waves to do the same job, and the company says the tech has proven to lower blood pressure by an average of 33 mm Hg in hypertensive patients. Of the large devicemakers in the renal denervation game, all but St. Jude Medical ($STJ) have used their checkbooks to enter the market, with Medtronic ($MDT) spending $800 million on Ardian and Covidien ($COV) plunking up to $230 million for Maya Medical. Factor in Boston Sci's recent deal, and ReCor would seem to be next on the block.

Likely acquirers: Well, who wants a piece of a market predicted to make billions over the next decade? Stryker ($SYK) hangs its hat on reconstructive devices, but new CEO Kevin Lobo has said the devicemaker is going through a paradigm shift, and the company made a splash last month when it bought Israel's Surpass Medical for $135 million to expand its neurological offerings. Same goes for Johnson & Johnson ($JNJ), which has set up "innovation centers" around the globe to ferret out potential deals.

For more:
Special Report: Renal Denervation - The Next Big Thing in Medical Devices
Boston Scientific jumps into renal denervation with $425M Vessix buy
Covidien grabs Maya Medical for $60M-plus

ReCor Medical